Black Diamond Therapeutics (BDTX)
(Real Time Quote from BATS)
$6.05 USD
-0.06 (-0.98%)
Updated Aug 30, 2024 01:58 PM ET
3-Hold of 5 3
D Value A Growth A Momentum B VGM
Brokerage Reports
Black Diamond Therapeutics, Inc. [BDTX]
Reports for Purchase
Showing records 41 - 60 ( 92 total )
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q4 Financials; Ph 1 BDTX-1535 Data on Track for 2H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q3 Financials; BDTX-1535 Update in 2023, BDTX-4933 IND in 1H:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- EORTC-NCI-AACR 2022: Covered Companies Roundup
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology - Relevant Abstracts at EORTC-NCI-AACR 2022
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q2 Financials; BDTX-1535 Trial on Track, Clinical Update in 2023
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
BDTX-189 Discontinued; Workforce Reduction Planned; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q4 Financials; Focus Shifts to BDTX-1535; Downgrading to NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
4Q21 Financial Results; Downgrading to Neutral Without Price Target
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Q3 Financials; BDTX-189 Ph 2 Set to Kick off, Three Additional INDs in 2022
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Multiple Preclinical Data Sets Presented at Triple Meeting; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Company: Black Diamond Therapeutics, Inc.
Industry: Medical - Drugs
Abstracts and Sessions Relevant to Covered Companies at AACR-NCI-EORTC
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R